Tubulis

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

Press releases

Press
14. March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Financing round co-led by EQT Life Sciences and Nextech Invest [1], with participation from current and new leading global biotechnology investors Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US MUNICH, GERMANY, March 14, 2024 – Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round
 
Press
3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of
 
Press
21. July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with support from Seventure Partners, coparion, Bayern Kapital, and OCCIDENT alongside significant contributions by high net worth individuals and the founders. Tubulis was s
 

Info & Contact

Address

Tubulis GmbH
Butenandtstraße 1
81377 Munich
Germany

In portfolio

17. Jul 2020

Sector

HTGF Manager

 
Dr. Frank Hensel, Principal / Authorized signatory